Kazia Therapeutics launches proposed public offering of ordinary shares
Oncology company Kazia Therapeutics initiated a proposed public equity offering to fund clinical advancement across its pipeline of targeted cancer and anti tumour therapies
Sydney, August 28, 2026 - Kazia Therapeutics Limited, a biotechnology company specializing in oncology, has initiated a phased public offering of its ordinary shares and warrants. The Offering, consisting of American Depositary Shares (ADSs) and accompanying Series A and Series B Warrants, is designed to facilitate the company's clinical development of paxalisib and other oncology indications.
The ADSs and Warrants are being offered under a registration statement on Form F-3, effective by the Securities and Exchange Commission (SEC). The net proceeds from the Offering will primarily be used for clinical development and general corporate purposes. Leerink Partners and Guggenheim Securities are joint bookrunners, while BTIG, Needham & Company, and Laidlaw & Company serve as co-managers. The Offering's terms and size are contingent on market conditions, and completion is not assured.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
